Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products by the granting of “Cell Characterisation” European patent No. EP2609217

Release Date: March 28, 2019

Sistemic Ltd announce expansion of patent portfolio covering the use of microRNAs for quality assessment of stem cell therapy products by the granting of “Cell Characterisation” European patent No. EP2609217

The European Patent Office communicated its decision to grant European Patent No. EP2609217, in the name of Sistemic Scotland Ltd titled “Cell Characterisation”.

The patent covers the use of microRNA profiles for quality assessment of stem cells and derived cell therapy products.

This patent is also the first of a number of patent applications protecting Sistemic’s miRNA-based quality control assay, SistemPSCCheck™, which assesses the levels of residual pluripotent stem cells in derived cell preparations.

Grant of the patent was published in the European Patent Bulletin on 27th March 2019 and after this date, the publication of the patent can also be viewed on the ESPACENET website using the following link: http://worldwide.espacenet.com/ and entering the Patent No: EP2609217.